NHWA(SZ:002262) Zheng Quan Zhi Xing·2025-06-13 11:15Core Viewpoint - The legal opinion issued by Beijing Lifang Law Firm confirms the legality and validity of the procedures and results of Jiangsu Enhua Pharmaceutical Co., Ltd.'s 2025 first extraordinary general meeting of shareholders [1][6]. Group 1: Meeting Procedures - The extraordinary general meeting was convened by the second meeting of the seventh board of directors on May 27, 2025, and the notice was published on May 28, 2025 [2][3]. - The notice included details about the meeting's time, location, voting rights, and registration methods for shareholders [3][4]. - The meeting was held on June 13, 2025, combining on-site voting and online voting through the Shenzhen Stock Exchange trading system [3][4]. Group 2: Participant Qualifications - A total of 353 participants attended the meeting, representing 487,253,371 shares, which is 5.1838% of the total voting shares [4][5]. - The qualifications of the shareholders and their representatives were verified and deemed valid [5][6]. Group 3: Voting Procedures and Results - The voting was conducted through a combination of on-site and online methods, with the results aligning with the previously announced agenda [5][6]. - The meeting's resolutions required a two-thirds majority approval from the attending shareholders for special resolutions [6].